Online inquiry

IVTScrip™ mRNA-Anti-MS4A1, AME-133v(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ2342MR)

This product GTTS-WQ2342MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets MS4A1 gene. The antibody can be applied in Non-Hodgkin's lymphoma (NHL) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001048028.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 485430
UniProt ID Q3C2E2
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MS4A1, AME-133v(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ2342MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ15608MR IVTScrip™ mRNA-Anti-SLC29A2, VAL-1221(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA VAL-1221
GTTS-WQ10850MR IVTScrip™ mRNA-Anti-FOLR1, M9346A(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA M9346A
GTTS-WQ9400MR IVTScrip™ mRNA-Anti-PTPRC, Iomab-B(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA Iomab-B
GTTS-WQ520MR IVTScrip™ mRNA-Anti-CD40, 4D11(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA 4D11
GTTS-WQ15807MR IVTScrip™ mRNA-Anti-CD3E&IL3RA, XmAb14045(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA XmAb14045
GTTS-WQ8422MR IVTScrip™ mRNA-Anti-HSP90, HSP90mab(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA HSP90mab
GTTS-WQ10438MR IVTScrip™ mRNA-Anti-MSTN, LY-2495655(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA LY-2495655
GTTS-WQ11141MR IVTScrip™ mRNA-Anti-IFNA1, MDX-1103(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA MDX-1103
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW